U.S. study targeting Spinal cord injury treatment based human embryonic stem cells

[foffana]

The U.S. biotech company Geron Corp. of Menlo Park, California announced it plans to start this summer a long-awaited project aimed at spinal cord injury targeting treatment based on human embryonic stem cells.

The company gained federal permission this week to inject eight to ten patients with cells derived from embryonic cells. The company president added that the patients will be paraplegics, who can use their arms but can't walk. Doctors aim to test the safety of the procedure, but they will also look for signs of improvement like return of sensation or movement in the legs.

The prsedident also said he can't estimate how much such a therapy would cost if it proves effective, but the company expectation is not going to be a $500,000 price tag. He hopes the cost will be remarkably affordable in the context of the value it provides.

Read more about American 1st stem cell study for spinal cord injury

[carbar]

Hallelujah!